RT Journal Article
SR Electronic
T1 Predicting disability progression and cognitive worsening in multiple sclerosis using grey matter network measures
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.23.21253388
DO 10.1101/2021.03.23.21253388
A1 Elisa Colato
A1 Jonathan Stutters
A1 Carmen Tur
A1 Narayanan Sridar
A1 Douglas Arnold
A1 Claudia Wheeler Kingshott
A1 Frederik Barkhof
A1 Olga Ciccarelli
A1 Declan Chard
A1 Arman Eshaghi
YR 2021
UL http://medrxiv.org/content/early/2021/03/26/2021.03.23.21253388.abstract
AB Objective In multiple sclerosis (MS), magnetic resonance imaging (MRI) measures at the whole brain or regional level are only modestly associated with disability, while network-based measures are emerging as promising prognostic markers. We sought to demonstrate whether data-driven network-based measures of regional grey matter (GM) volumes predict future disability in secondary progressive MS (SPMS).We used cross-sectional structural MRI, and baseline and longitudinal data of Expanded Disability Status Scale [EDSS], 9-Hole Peg Test [9HPT], and Symbol Digit Modalities Test [SDMT], from a clinical trial in 988 people with progressive MS. We processed T1-weighted scans to obtain GM probability maps and applied spatial independent component analysis (ICA) to identify co-varying patterns of GM volume change. We used survival models to determine whether baseline GM network measures predict cognitive and motor worsening.Results We identified 15 networks of regionally co-varying GM features. Compared with whole brain GM, deep GM, and lesion volumes, ICA-components correlated more closely with clinical outcomes. A mainly basal ganglia component had the highest correlations at baseline with the SDMT and was associated with cognitive worsening (HR= 1.29, 95% CI [1.09-1.52], p< 0.005). Two ICA-components were associated with 9HPT worsening (HR=1.30, 95% CI [1.06:1.60], p<0.01; and HR= 1.21, 95%CI [1.01:1.45], p<0.05). Post-hoc analyses revealed that for 9HPT and SDMT survival models including network-based measures reported a higher discrimination power (respectively, C-index= 0.69, se= 0.03; C-index= 0.71, se= 0.02) compared to models including only whole and regional MRI measures (respectively, C-index= 0.65, se= 0.03; C-index= 0.69, se= 0.02).Conclusions The disability progression was better predicted by networks of covarying GM regions, rather than by single regional or whole-brain measures. Network analysis can be applied in future clinical trials and may play a role in stratifying participants who have the most potential to show a treatment effect.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01416181Funding StatementThis study was supported by the International Progressive MS Alliance (IPMSA, award reference number PA-1603-08175). We are grateful to all the IPMSA investigators who have contributed trial data to this study as part of EPITOME: Enhancing Power of Intervention Trials Through Optimized MRI Endpoints network. DC, FB and OC are supported by the NIHR biomedical research centre at UCLHAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board at the Montreal Neurological Institute (MNI), Quebec, Canada approved this study under the auspices of International Progressive MS Alliance (Reference number: IRB00010120).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesProcessed data and codes used in this study are available upon request from qualified investigators.Abbreviations9HPT9-Hole Peg TestC-indexConcordance IndexCDPConfirmed Disability ProgressionCNSCentral Nervous SystemCSFCerebro-Spinal FluidDGMDeep Grey MatterEDSSExpanded Disability Status ScaleFWHMull Width At Half MaximumGMGrey matterHRHazard RatioICAIndependent Component AnalysisMRIMagnetic Resonance ImagingMSMultiple SclerosisSDMTSymbol Digit Modalities TestSPMSSecondary Progressive Multiple SclerosisWMWhite Matter